Clinical Trials Logo

Chronic Kidney Disease clinical trials

View clinical trials related to Chronic Kidney Disease.

Filter by:

NCT ID: NCT04115345 Completed - Clinical trials for Chronic Kidney Disease

A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).

Start date: August 13, 2019
Phase: Phase 1
Study type: Interventional

A phase 1, open-label safety, tolerability and early efficacy study of a Renal Autologous Cell Therapy (REACT) in patients with Chronic Kidney Disease from Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) (REGEN-004)

NCT ID: NCT04072341 Completed - Clinical trials for Chronic Kidney Disease Requiring Chronic Dialysis

Effects of Green Propolis Extract (EPP-AF) on Inflammation in Hemodialysis Patients.

Start date: August 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

End-stage chronic kidney disease is associated with the condition of chronic inflammation. Patients on hemodialysis are known to be predisposed to several factors that predispose to inflammation: dialysis membranes, central venous catheters, oxidative stress, fluid overload, sodium overload, uraemic toxins. Propolis, a natural resin produced by bees from plant materials, has anti-inflammatory, immunomodulatory, and anti-oxidant properties. The aim of this study was to evaluate the impact of Brazilian green propolis extract on inflammation in hemodialysis patients.

NCT ID: NCT04034992 Completed - Clinical trials for Chronic Kidney Disease

A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, Effect of the Treatment, Patient Outcomes and Patient Quality of Life

Start date: September 11, 2019
Phase:
Study type: Observational

DISCOVER CKD is an international observational cohort study in patients with CKD, comprising both prospective and retrospective patient cohorts. The study does not attempt to test any specific a priori hypotheses, is largely descriptive, and utilises data collected only under conditions of routine clinical care.

NCT ID: NCT04032613 Completed - Clinical trials for Chronic Kidney Disease

Breaking Down Care Process and Patient-level Barriers to Arteriovenous Access Creation Prior to Hemodialysis Initiation

Start date: July 30, 2019
Phase: N/A
Study type: Interventional

More than 80% of individuals in the U.S. start maintenance hemodialysis (HD) with a central venous catheter, despite substantial evidence that starting HD with an arteriovenous (AV) access improves quality of life, lowers mortality, and decreases healthcare costs. Health system- and patient-level barriers contribute to low rates of AV access creation prior to HD initiation. Evidence-based, pre-dialysis interventions to improve these low rates and associated clinical outcomes are lacking. A Vascular Access Navigation and Education Quality Improvement Program will be implemented in the Geisinger Danville, PA chronic kidney disease clinic. Individuals who choose to participate in a research sub-study of the program will complete questionnaires to assess their vascular access care knowledge and confidence before and after participation in the quality improvement program.

NCT ID: NCT04024501 Completed - Clinical trials for Chronic Kidney Disease

A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition

Start date: July 20, 2019
Phase: Phase 1
Study type: Interventional

This study is intended to assess the relative bioavailability between the (extended-release) ER8 capsule formulation (the formulation that is currently used for verinurad development) given under fasted conditions and 2 new capsule formulations of verinurad (A-capsule and B-capsule) given under fed or fasted conditions. All three capsules target an 8-hour release profile (extended-release). The highest dose (12 mg) currently tested in participants will be tested in this study. The study is designed to provide information to optimize the verinurad part of a fixed dose combination capsule to be used in future development.

NCT ID: NCT04017572 Completed - Clinical trials for End Stage Kidney Disease

Optimized vs. Standard Automated Peritoneal Dialysis Regimens Study

OptiStAR
Start date: June 1, 2019
Phase: N/A
Study type: Interventional

This clinical study is designed to evaluate the theoretical prediction of a lower glucose absorption in optimized automated peritoneal dialysis regimes. Patients will receive both a standard 6 x 2L 1.36% glucose regime or an optimized 7 x 2 L 2.27% glucose + 5 x 2 L 0.1% glucose regime in a crossover fashion.

NCT ID: NCT03990363 Completed - Clinical trials for Chronic Kidney Disease

A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia

SAPPHIRE
Start date: July 23, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to establish the dose of verinurad combined with allopurinol 300 mg once daily that will elicit the desired response; ie, reduction in urinary albumin to creatinine ratio (UACR) at 6 months.

NCT ID: NCT03976115 Completed - Clinical trials for Chronic Kidney Disease

A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease

Start date: July 18, 2019
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, dose-escalating, placebo controlled, Phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of DDO-3055 in healthy volunteers and patients with chronic kidney disease. 48 healthy volunteers will be enrolled in Part A, and 18 patients with chronic kidney disease will be enrolled in Part B.

NCT ID: NCT03960437 Completed - Clinical trials for Vascular Calcification

The Effect of Etelcalcetide on CKD-MBD

Parsabiv-MBD
Start date: September 6, 2018
Phase: Phase 2
Study type: Interventional

The proposed study will investigate the effects of etelcalcetide on the bone and blood-vessel health in patients with CKD-MBD. The investigators will test if etelcalcetide makes bone and blood-vessels healthier. The study hypotheses are that are that etelcalcetide keeps bones strong and lowers the risk of calcium deposits in blood vessels. In Aim 1, the investigators will test if 9-months of treatment with etelcalcetide improves bone strength in twenty ESKD patients with hyperparathyroidism (HPT) by bone biopsy. In Aim 2, the investigators will test if 9-months of treatment with etelcalcetide decreases serum propensity to calcify blood vessels. The potential significance of this study is to provide first-time data on the ability of etelcalcetide to protect bone and blood-vessel health in patients with ESKD.

NCT ID: NCT03942744 Completed - Clinical trials for Chronic Kidney Disease Requiring Chronic Dialysis

The Effect of High-flux Hemodialysis and On-line Hemodiafiltration on Endothelial Function.

Start date: November 8, 2018
Phase: N/A
Study type: Interventional

The main aim of this project is to evaluate, in patients with chronic kidney disease (CKD5D), the role of adhesion molecules in leukocyte adhesion and transendothelial migration involved in atherogenesis. This trial is a prospective randomized crossover study in CKD5D hemodialysis patients followed in the Nephrology Unit of the Reina Sofia University Hospital (Cordoba, Spain). The estimated inclusion period is two years, with a follow-up of 24 months. Patients will be randomized to high-flux hemodialysis versus online hemodiafiltration with high convective transport (above 21 liters); after 6 months in each dialysis modality they will be switched the other technique for another 6 months. Then, patients will be maintained during 4 weeks in conventional hemodialysis "wash out period", before being started in the other dialysis modality.